Research Papers

25 of 127 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Interferons in the treatment of myeloproliferative neoplasms.
Vachhani P; Mascarenhas J; Bose P; Hobbs G; Yacoub A; Palmer JM; Gerds AT; Masarova L; Kuykendall AT; Rampal RK; Mesa R; Verstovsek S.
Ther Adv Hematol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
When idiopathic multicentric Castleman disease meets COVID-19: a multicenter retrospective study from China.
Liu Y; Yin X; Xu D; Lv Y; Zhu L; Yang M; Yao Q; Jin J; Huang L; Meng H; You L.
Ther Adv Hematol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Treatment of multiple myeloma with selinexor: a review.
Huang Q; Zhao R; Xu L; Hao X; Tao S.
Ther Adv Hematol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-a…
Lee J; Lee H; Kim S; Suh HS.
Ther Adv Hematol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors:…
Atallah E; Saini L; Maegawa R; Rajput T; Corbin R; Viana R.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years…
Feng R; Zhang S; Li JT; Wang T; Zhang CL; Bai JF; Yang L; Wang LR; Jing HM; Liu H.
Ther Adv Hematol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeu…
Mannelli F; Crupi F; Zanotti R; Pagano L; Rapezzi D; Tanasi I; Criscuolo M; Bonifacio M; Fresa A; Guglielmelli P; Vannucchi AM.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Assessment of risk factors for acute graft-<i>versus</i>-host disease post-hematopoietic stem cell transplantation: a r…
Xue L; Song L; Yu X; Yang X; Xia F; Ding X; Huang C; Wu D; Miao L.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context.
Astermark J; Baghaei F; Strandberg K; Toplican PG; Birkedal MF; Grahn EE; Hansson C; Kampmann P; Lehtinen AE; Täckström K; Holme PA; Magnusson M.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia.
Briski R; Garcia-Manero G; Kantarjian H; Ravandi F.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with…
Kantarjian HM; Logan AC; Zaman F; Gökbuget N; Bargou RC; Zeng Y; Zugmaier G; Locatelli F.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center ret…
Zhang Z; Hu Q; Yang C; Chen M; Han B.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Non-invasive prenatal testing for fetal Ss, Kidd, and CTL2 blood group prediction by multiplex digital droplet PCR.
Wang Y; Chu X; Chen X; Yin A; Yao Y; Wang L; Xu H; Liu F; Chen K; Wu Y.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Immune dysregulation and potential targeted therapy in myelodysplastic syndrome.
Zhang X; Yang X; Ma L; Zhang Y; Wei J.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA …
Ettingshausen CE; Hermans C; Holme PA; Cid AR; Khair K; Oldenburg J; Négrier C; Botha J; Lelli A; Windyga J.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (…
Welslau M; Kubuschok B; Topaly J; Otremba B; Wolff T; Bryn G.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations…
Escuriola-Ettingshausen C; Klamroth R; Escobar M; Stasyshyn O; Tangada S; Engl W; Honauer I; Lee HY; Chowdary P; Windyga J.
Ther Adv Hematol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study.
Oladapo A; Kolodny S; Vredenburg M; Swallow E; Goldschmidt D; Sarathy K; Lopez P; Maitland H; Yee J.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opi…
Lucchesi A; Fattizzo B; De Stefano V; Ruggeri M; Siragusa S; Vianelli N; Zaja F; Rodeghiero F.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a natio…
Tsai TH; Yu LH; Yu MS; Huang SH; Lin AJ; Lee KD; Chen MC.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory…
Jurczak W; Elmusharaf N; Fox CP; Townsend W; Paulovich AG; Whiteaker JR; Krantz F; Wun CC; Parr G; Sharma S; Munugalavadla V; Manwani R; Dean E; Munir T.
Ther Adv Hematol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in …
Li N; Lei J; Zhang J; Cai H; Zheng B; Yang T; Liu M; Hu J.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.
Wang H; Berger KN; Miller EL; Fu W; Broglie L; Goldman FD; Konig H; Lim SJ; Berg AS; Talano JA; Comito MA; Farag SS; Pu JJ.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Considerations for shared decision management in previously untreated patients with hemophilia A or B.
Astermark J; Blatný J; Königs C; Hermans C; Jiménez-Yuste V; Hart DP.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic …
Xu L; Lin S; Xing X; Su Y.
Ther Adv Hematol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared